# Expanded Access to Provide Larotrectinib for the Treatment of Cancers With a NTRK Gene Fusion

> **NCT03025360** · — · APPROVED_FOR_MARKETING · sponsor: **Bayer**

## Conditions studied

- Tumors Harboring NTRK Fusion

## Interventions

- **DRUG:** Larotrectinib (Vitrakvi, BAY2757556)

## Key facts

- **NCT ID:** NCT03025360
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** APPROVED_FOR_MARKETING
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2019-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03025360

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03025360, "Expanded Access to Provide Larotrectinib for the Treatment of Cancers With a NTRK Gene Fusion". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03025360. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*